Yuval Mika - Jan 26, 2023 Form 3 Insider Report for Orchestra BioMed Holdings, Inc. (OBIO)

Role
General Manager and Chief Technology Officer, Bioelectronic Therapies Exhibit 24 - Power of Attorney
Signature
/s/ Matthew Schob, Attorney-in-Fact
Stock symbol
OBIO
Transactions as of
Jan 26, 2023
Transactions value $
$0
Form type
3
Date filed
1/30/2023, 08:21 PM
Next filing
May 5, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding OBIO Warrants (Right to Buy) Jan 26, 2023 Common Stock, par value $0.0001 per share ("Common Stock") 50K $11.50 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 50% of the shares of Common Stock underlying the Warrants will vest and become exercisable on January 26, 2025 and the remaining 50% of the shares of Common Stock underlying the Warrants will vest and become exercisable on January 26, 2026, in each case subject to the Reporting Person's continued employment or service with the Company or one of its subsidiaries through such dates.

Remarks:

General Manager and Chief Technology Officer, Bioelectronic Therapies Exhibit 24 - Power of Attorney